75/100BSanofi ADS stock forecast 2026–2029What is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
Analysts' average 12-month price target for Sanofi ADS is 53.00, 12.7% above the current price of 47.01. Their targets range from 49.00 to 57.00.
Of the 7 firms that rated Sanofi ADS in the past 12 months, 0 rate it buy or strong buy, 7 hold and 0 sell or strong sell (each firm at its latest rating): a Hold consensus.
Analysts' 1-year price targets range from 49.00 to 57.00, with an average of 53.00.
| Buy | 0 | |
| Hold | 7 | |
| Sell | 0 |
12-month price target
| Highest target | 57.00 |
| Average target | 53.00 |
| Lowest target | 49.00 |
| Current price | 47.01 |
Sanofi ADS price target historyWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
How analysts rate Sanofi ADS, month by monthWhat is the analyst rating? The analyst rating sums up what the analysts covering a stock recommend, from strong buy to strong sell, by the share of them rating it a buy.
0 of 7 firms rate it buy now, against 2 of 4 in December 2025.
Each month: every firm at its latest rating from the 12 months before. Strong buys count as buys, strong sells as sells.
Sanofi ADS analyst upgrades, downgrades and price targets
The latest rating change came on 1 May 2026, when Morgan Stanley downgraded Sanofi ADS from Overweight to Equal Weight. Its price target is 52.00, from 56.00. The most recent new target came from BNP Paribas on 9 November 2026: 57.00.
| Date | Firm | Rating | Price target | Change | Price then |
|---|---|---|---|---|---|
| 9 Nov 2026 | BNP Paribas Peter Verdult | — | 50.00 → 57.00 | +14.0% | 47.04 |
| 8 Jul 2026 | Morgan Stanley Sarita Kapila | — | 52.00 → 49.00 | -5.8% | 42.98 |
| 1 May 2026 | Morgan Stanley | Downgraded · Overweight → Equal Weight | 56.00 → 52.00 | -7.1% | 46.08 |
| 20 Apr 2026 | BNP Paribas Peter Verdult | — | 50.00 | — | 48.06 |
| 20 Apr 2026 | Exane BNP Paribas | Downgraded · Outperform → Neutral | — | — | — |
| 12 Feb 2026 | B of A Securities | Downgraded · Buy → Neutral | — | — | — |
| 16 Jan 2026 | UBS | Downgraded · Buy → Neutral | — | — | — |
| 6 Jan 2026 | Barclays | Downgraded · Overweight → Equal Weight | — | — | — |
| 9 Dec 2025 | Guggenheim | Downgraded · Buy → Neutral | — | — | — |
| 8 Dec 2025 | JP Morgan | Downgraded · Overweight → Neutral | — | — | — |
Sanofi ADS EPS and revenue estimatesWhat are estimate revisions? Estimate revisions are the changes analysts make to their EPS and revenue forecasts for the years ahead. They show whether expectations are rising or falling.
Analysts expect Sanofi ADS's EPS to grow 17.0% a year until 2027. Over the last 5 years it fell 8.2% a year, and over the last 3 years it grew 0.2%.
Analysts expect Sanofi ADS's revenue to grow 4.4% a year until 2028, about as fast as over the last 5 years (4.6% a year) and the last 3 years (4.8%).
Revenue
EPS
Does Sanofi ADS beat earnings estimates?What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
On average, analysts' EPS estimate was 8.0% off the result, either way, and their revenue estimate 15.5%, over the last 12 quarters.
- EPS beats
- 47 / 74
- Revenue beats
- 49 / 57
- Average EPS surprise, last 12What is an earnings surprise? An earnings surprise is how far a company's reported EPS or revenue came above or below the analysts' average estimate, in percent.
- +5.9%
- Since
- May 2005
| Quarter | Report date | EPS estimate | Reported EPS | Surprise | Revenue estimate | Reported revenue | Surprise |
|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 30 Oct 2026 | 1.63 | 2.04 | +25.2% | 14.29B | 17.02B | +19.0% |
| Q2 FY2026 | 30 Jul 2026 | 1.10 | 1.21 | +10.0% | 15.34B | 14.06B | -8.3% |
| Q1 FY2026 | 23 Apr 2026 | 1.06 | 1.10 | +3.8% | 12.68B | 12.94B | +2.1% |
| Q4 FY2025 | 29 Jan 2026 | 0.84 | 0.89 | +6.0% | 11.71B | 14.34B | +22.4% |
| Q3 FY2025 | 24 Oct 2025 | 1.60 | 1.70 | +6.2% | 11.11B | 15.43B | +38.9% |
| Q2 FY2025 | 31 Jul 2025 | 0.96 | 0.90 | -6.2% | 12.36B | 12.64B | +2.3% |
| Q1 FY2025 | 24 Apr 2025 | 0.90 | 0.94 | +4.4% | 10.00B | 11.63B | +16.3% |
| Q4 FY2024 | 30 Jan 2025 | 0.71 | 0.70 | -1.4% | 9.51B | 7.90B | -16.9% |
| Q3 FY2024 | 25 Oct 2024 | 1.35 | 1.57 | +16.3% | 13.94B | 15.53B | +11.4% |
| Q2 FY2024 | 25 Jul 2024 | 0.86 | 0.93 | +8.1% | 14.76B | 12.24B | -17.1% |
| Q1 FY2024 | 25 Apr 2024 | 0.94 | 0.97 | +3.2% | — | 11.94B | — |
| Q4 FY2023 | 1 Feb 2024 | 0.94 | 0.89 | -5.3% | — | 25.17B | — |
Sanofi ADS stock price 2026–2029: scenariosHow are the stock price scenarios calculated? Bear, base and bull prices for the years ahead: the analysts' EPS estimates times the lowest, average and highest P/E of the stock today and at its last five year ends, or of its peers.
If Sanofi ADS's earnings keep growing at the 5.0% a year analysts expect to FY2027, it would earn about 5.39 a share in FY2029. At the P/E it has traded at over the last five years (12.9 to 21.2) that is 69.48 to 114.38 a share, or 93.70 at its average P/E of 17.4. This is arithmetic on the analysts' estimates, not a prediction.
| Fiscal year | EPS | Bear | Base | Bull |
|---|---|---|---|---|
| FY2026 | 4.59 | 59.11 | 79.72 | 97.32 |
| FY2027 | 4.89 | 62.98 | 84.94 | 103.69 |
| FY2028 (extrapolated) | 5.13 | 66.15 | 89.22 | 108.90 |
| FY2029 (extrapolated) | 5.39 | 69.48 | 93.70 | 114.38 |
Each year's EPS is the analysts' consensus to FY2027; the years after grow 5.0% a year (the analysts' growth, at most 15%). Bear, base and bull apply the lowest, average and highest P/E of today and the last five fiscal year ends, leaving out any above 60, the mark of a year of collapsed earnings (12.9, 17.4, 21.2).
Is Sanofi ADS stock undervalued or overvalued?How does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
Sanofi ADS's P/E of 71.5 is near the top of its 5-year range (10.1 to 83.1, median 17.9). Analysts expect faster growth than in recent years, which can explain part of the high P/E. Growing 17.0% a year, Sanofi ADS earns a P/E of 17.0 at a PEG of 1 (at most 25): × the next twelve months' EPS of 4.84, a fair value of 82.55; the price, 47.01, is 43.1% below it. Its forward P/E, on the consensus for FY2026, is 10.3.
Fair value on growth is a P/E equal to the EPS growth analysts expect a year (a PEG of 1, at most 25) times the earnings per share of the next twelve months; the ends of the bar are a PEG of 0.75 and 1.25 (a P/E of 12.8 and 21.3). The price against its P/E range
- Price to earnings ratio (TTM)What is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 71.48
- Five-year median P/EWhat is the P/E ratio? The P/E ratio divides a share's price by its earnings per share over the last year: what you pay for each dollar of profit.
- 17.90
- Five-year P/E range
- 10.1 – 83.1
- Forward P/E (FY2026)What is the forward P/E ratio? Forward P/E divides a share's price by the earnings per share analysts expect in the coming year, rather than last year's actual earnings.
- 10.25
- PEG ratioWhat is the PEG ratio? The PEG ratio divides the P/E by the yearly earnings growth analysts expect, to show how much you pay for each point of growth.
- 14.22
- To the average targetWhat is an analyst price target? A price target is the price an analyst expects a stock to reach in 12 months. Arincen shows the average, high and low targets and the upside to the average.
- +12.7%
Most undervalued US stocksHow does Arincen work out a stock's fair value? Fair value is our estimate of a share's price at the P/E the company usually trades at, with a low to high range around it.
| Stock | Price | Fair value | Upside |
|---|---|---|---|
| 99.090 | 194.93146Price 99.09244 | +96.7% | |
| 42.225 | 82.9546Price 42.23165 | +96.4% | |
| 186.680 | 360.82271Price 186.68451 | +93.3% | |
| 213.670 | 405.57304Price 213.67507 | +89.8% | |
| 161.160 | 305.51157Price 161.16396 | +89.6% | |
| 160.650 | 300.09225Price 160.65375 | +86.8% | |
| 165.860 | 308.95212Price 165.86442 | +86.3% |
Furthest below the fair value on each stock's page, updated every day.